基于《中国医疗机构药品评价与遴选快速指南(第二版)》的血凝酶类药物临床综合评价  

Clinical Comprehensive Evaluation on Hemocoagulase Drugs Based on A Quick Guideline for Drug Evaluation and Selection in Chinese Medical Institutions(the Second Edition)

作　　者：王亚云 魏安华 王璐 贡雪芃 刘东[1] 曾露[1] WANG Yayun;WEI Anhua;WANG Lu;GONG Xuepeng;LIU Dong;ZENG Lu(Department of Pharmacy,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China;Department of Pharmacy,the People's Hospital of Jianli City,Hubei Province,Jianli 433300,China)

机构地区：[1]华中科技大学同济医学院附属同济医院药学部,武汉430030 [2]湖北省监利市人民医院药剂科,监利433300

出　　处：《医药导报》2025年第2期245-250,共6页Herald of Medicine

摘　　要：目的对血凝酶类药物进行多维度评价,为临床用药及医疗机构遴选药物提供参考数据。方法基于《中国医疗机构药品评价与遴选快速指南(第二版)》评价体系,调整部分评分细则,参考药品说明书、临床指南及中国知网、万方、维普、PubMed、Embase、Cochrane Library等数据库相关文献,从药学特性、有效性、安全性、经济性、其他属性(医保、基本药物、生产企业等)5个维度对我国已上市的4种血凝酶类药物进行量化评分,并依据评分结果划分推荐级别。结果量化评分结果从高到低排序分别为注射用尖吻蝮蛇血凝酶(68.50分)、注射用白眉蛇毒血凝酶(59.89分)、蛇毒血凝酶注射液(52.84分)和注射用矛头蝮蛇血凝酶(49.31分)。结论血凝酶类药物整体得分偏低,有替代药品时可优选其他止血药物,其中注射用尖吻蝮蛇血凝酶在医疗机构中为弱推荐。该研究可为医疗机构血凝酶类药物遴选提供参考,也为临床合理用药提供依据。Objective The multi-dimensional evaluation of hemocoagulase drugs was carried out to provide reference data for clinical drug use and drug selection in medical institutions.Methods According to the evaluation system established by the A Quick Guideline for Drug Evaluation and Selection in Chinese Medical Institutions(the Second Edition),part of the scoring rules was adjusted,and relevant literatures from CNKI,Wanfang,VIP,PubMed,Embase,Cochrane Library and other databases were referred to.Four hemocoagulase drugs listed in China were quantitatively scored from five dimensions:pharmaceutical properties,effectiveness,safety,economy and other attributes(medical insurance,essential drugs,manufacturers,etc.).The recommendation levels were divided according to the scoring results.Results The quantified scoring results,in descending order,were ashaemocoagulaseagkistrodon(HCA)(68.50 points),hemocoagulaseagkistrodonhalys(HAH)(59.89 points),hemocoagulase injection(HI)(52.84 points)and hemocoagulasebothropsatrox(HBA)(49.31 points).Conclusions The overall score of hemocoagulase drugs is low,and other hemostatic drugs can be preferred when alternative drugs are available.Among them,the HCA is weakly recommended in medical institutions.This study can provide reference for the selection of hemocoagulase drugs in medical institutions,and also provide basis for clinical rational drug use.

关 键 词：血凝酶 止血药 药品评价 药物遴选 

分 类 号：R973.1[医药卫生—药品]